Loading
A phase 1/2 trial of JMT203 Injection in non-small-cell lung cancer, pancreatic ductal adenocarcinoma and colorectal cancer, run by Shanghai JMT-Bio Inc., now recruiting.
A Study of JMT203 in Patients With Cancer Cachexia is a phase 1/2 interventional study registered as NCT06868849 by Shanghai JMT-Bio Inc., with 307 participants planned, started 2024-05-15 and due to reach its primary completion in 2027-08-14. Interventions recorded: JMT203 Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares CSPC Pharmaceutical Group, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares CSPC Pharmaceutical Group, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares CSPC Pharmaceutical Group, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/